AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 09:20:34 2024-06-27 EDT			5-day change	1st Jan Change
12,484 ^GBX	-0.57%		+0.77%	+17.87%

12:39pm	US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	RE
06-26	European Equities Close Lower in Wednesday Trading	MT

Serum Institute, Indian Maker Of Astrazeneca Vaccine, Says Should Be Able To Supply 300 Mln Doses To Indian Govt By July/August; No Formal Supply Deal Signed Yet

January 03, 2021 at 09:50 am

SERUM INSTITUTE, INDIAN MAKER OF ASTRAZENECA VACCINE, SAYS SHOULD BE ABLE TO SUPPLY 300 MLN DOSES TO INDIAN GOVT BY JULY/AUGUST; NO FORMAL SUPPLY DEAL SIGNED YET

Latest news about AstraZeneca PLC

US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06:39am	RE
European Equities Close Lower in Wednesday Trading	06-26	MT
ASTRAZENECA : Deutsche Bank sticks Neutral	06-26	ZD
AstraZeneca Says Tagrisso With Chemotherapy Approved in China	06-26	MT
AstraZeneca: Tagrisso approved in China for NSCLC	06-26	CF
AstraZeneca's Tagrisso plus chemo gets approval in China	06-26	AN
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment	06-26	RE
AstraZeneca Wins Chinese Regulatory Nod for Lung Cancer Combination Treatment	06-26	MT
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws	06-25	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	06-25	MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	06-25
AstraZeneca Says Imfinzi With Chemotherapy Improves Survival in Phase 3 Bladder Cancer Trial	06-25	MT
AstraZeneca's Tagrisso Approved With Chemotherapy in Japan for Lung Cancer Treatment	06-25	MT
AstraZeneca Says Phase 3 Imfinzi Trial in Early-Stage Lung Cancer Misses Primary Endpoint	06-25	MT
AstraZeneca Logs Hit and Miss in Oncology Drugs Portfolio	06-25	MT
AstraZeneca PLC Announces IMFINZI Demonstrates Statically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in Niagara Phase III Trial	06-25	CI
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers	06-25	RE
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	06-25	ZD
AstraZeneca: inconclusive trial for Infinzi in NSCL	06-25	CF
AstraZeneca: Tagrisso protocol approved in Japan	06-25	CF
AstraZeneca: inconclusive trial for Infinzei in NSCL	06-25	CF
AstraZeneca: conclusive trial in bladder cancer	06-25	CF
AstraZeneca details mixed findings from cancer drug trials	06-25	AN
Correction: AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	06-25	MT
AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	06-25	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

158.5 USD

Average target price

174.4 USD

Spread / Average Target

+10.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+17.87%	246B
ELI LILLY AND COMPANY	+54.61%	811B
NOVO NORDISK A/S	+43.65%	640B
JOHNSON & JOHNSON	-6.33%	353B
MERCK & CO., INC.	+20.62%	333B
ABBVIE INC.	+10.44%	302B
ROCHE HOLDING AG	+2.41%	225B
NOVARTIS AG	+12.61%	218B
AMGEN INC.	+8.61%	168B
PFIZER, INC.	-4.76%	155B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Serum Institute, Indian Maker Of Astrazeneca Vaccine, Says Should Be Able To Supply 300 Mln Doses To Indian Govt By July/August; No Formal Supply Deal Signed Yet

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals